How technology can help you draw conclusions on DDI risk and clinical significance for your target patient population
Evaluating drug-drug interactions (DDIs) early in development allows you to assess potential concomitant medication risk for your target patient population and determine whether a dedicated DDI clinical study is necessary. A thorough DDI analysis helps you move forward with confidence and ensure that patients can safely take new medications with their existing treatments.
This comprehensive white paper discusses the complexities of transporter-mediated DDIs and explores how Certara’s Drug Interaction Database or DIDB can help streamline the evaluation process using scientist-curated in vitro and clinical datasets.
Submit the form to download your free copy of the transporter-mediated DDI white paper today
Learn more about the complexities of transporter-based DDIs compared to CYP-mediated interactions and the valuable insights into transporter-based drug interactions available through the DIDB platform.
The white paper outlines practical strategies for leveraging DIDB to:
- Evaluate a new molecular entity or NME’s inhibitory potential on transporters
- Identify relevant transporter substrates administered in your target patient population
- Assess drug interaction clinical significance of these co-medications
- Determine whether a dedicated clinical DDI study is necessary
作者：
Isabelle Ragueneau-Majlessi, MD, MS
高级总监
Dr. Ragueneau is a Clinical Professor Emeritus from the University of Washington where she co-founded the Drug Interaction Database or DIDB over 25 years ago. 在 Certara，她是药物相互作用解决方案项目的负责人，并领导药物相互作用科学卓越中心。她是一名临床药理学家，在评估药物相互作用机制和临床意义方面具有深厚的专业知识。2022 年，她因在药物相互作用数据库方面所做的大量工作以及该工具对药物相互作用研究的影响，获得了美国药物滥用和不良反应学会颁发的 Gary Neil 药物开发创新奖。
Jingjing Yu, MD, PhD
总监
在收购华盛顿大学药物相互作用解决方案项目后，Dr. Yu 于 2023 年加入 Certara。她在药物代谢和临床药理学领域拥有超过 15 年的经验，通过在学术界和工业界的工作，她在药物相互作用领域积累了独特的专业知识。在 Certara，Dr. Yu 是药物相互作用解决方案总监，也是药物相互作用科学卓越中心的核心成员。她还是华盛顿州西雅图华盛顿大学制药系的副教授。
